MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
EyePoint Pharmaceuticals Long-Term Debt 2011-2025 | EYPT
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt EyePoint Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.9 M | 4.91 M | 29.3 M | 36.6 M | 38 M | 47.2 M | 17.3 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 47.2 M | 4.91 M | 27.9 M |
Quarterly Long-Term Debt EyePoint Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.3 M | 21.8 M | 22.3 M | 21.9 M | 21.9 M | 22.2 M | - | 4.91 M | - | - | 29.4 M | 29.3 M | 29.3 M | - | 29.1 M | 36.6 M | 36.4 M | 36.2 M | 38.1 M | 38 M | 38 M | 38 M | 38 M | 47.2 M | 47.2 M | 47.2 M | 47.2 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 47.2 M | 4.91 M | 30.1 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
2.12 M | $ 3.01 | -0.66 % | $ 233 M |  USA |
 |
Aptevo Therapeutics
APVO
|
4.63 M | $ 0.55 | -9.41 % | $ 152 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
59.9 K | $ 3.2 | 0.95 % | $ 7.7 B |  Australia |
 |
Autolus Therapeutics plc
AUTL
|
47.9 M | $ 1.88 | 12.57 % | $ 480 M |  Britain |
 |
Alpine Immune Sciences
ALPN
|
3.38 M | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M |  France |
 |
Aptorum Group Limited
APM
|
130 K | $ 1.14 | -0.35 % | $ 6.22 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
2.63 M | - | 1.93 % | $ 17.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | USA |
 |
BioVie
BIVI
|
275 K | $ 1.19 | -2.07 % | $ 1.76 M | USA |
 |
AlloVir
ALVR
|
16.6 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
49 K | - | - | $ 10.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
188 K | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
78.5 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
8.76 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
755 K | - | 1052.0 % | $ 415 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
25.7 M | - | -9.72 % | $ 5.89 M | USA |
 |
Acasti Pharma
ACST
|
410 K | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
19.9 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
22.7 M | - | -7.31 % | $ 87 M | USA |
 |
Albireo Pharma
ALBO
|
9.62 M | - | -0.23 % | $ 916 M | USA |
 |
Catalyst Biosciences
CBIO
|
199 K | $ 12.25 | -0.85 % | $ 806 M | USA |
 |
BioNTech SE
BNTX
|
231 M | $ 94.77 | 0.26 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
614 M | $ 26.88 | -0.88 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
166 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
1.67 M | - | -10.95 % | $ 876 K | USA |
 |
Certara
CERT
|
292 M | $ 8.84 | -0.56 % | $ 1.42 B | USA |
 |
Anika Therapeutics
ANIK
|
26.9 M | $ 9.51 | -0.42 % | $ 139 M | USA |
 |
bluebird bio
BLUE
|
37.7 M | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
14.7 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
146 K | - | 2.71 % | $ 14 M | USA |
 |
Cellectis S.A.
CLLS
|
28.8 M | $ 4.95 | 4.21 % | $ 116 M | France |
 |
Axon Enterprise
AXON
|
41.4 M | $ 581.18 | -0.45 % | $ 44 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.33 M | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
10.9 M | $ 2.5 | 2.04 % | $ 15.7 M | USA |
 |
ChromaDex Corporation
CDXC
|
12 K | - | -0.88 % | $ 598 M | USA |
 |
AstraZeneca PLC
AZN
|
17.5 B | $ 92.61 | -0.31 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
167 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | USA |
 |
Celldex Therapeutics
CLDX
|
2.36 M | $ 26.01 | -1.48 % | $ 1.67 M | USA |